| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | -0.0076 | 0.8 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | -0.0069 | 0.8 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | NSC-87877 | GDSC1000 | pan-cancer | AAC | -0.0072 | 0.8 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | 0.0055 | 0.8 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.8 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.0066 | 0.8 |